Levodropropizine
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 11–14% |
| Metabolism | Liver (conjugation and para-hydroxylation)[2] |
| Elimination half-life | 2.3 [1] |
| Excretion | 83% via urine within 96 h |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.167.719 |
| Chemical and physical data | |
| Formula | C13H20N2O2 |
| Molar mass | 236.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Levodropropizine is a cough suppressant. It is the levo isomer of dropropizine. It acts as a peripheral antitussive, with no action in the central nervous system.[3] It does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives.
In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as patent infringement protection for its 2017 registered antitussive drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine."[4] In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its mucoactive drug, Levotics CR Tab (levodropropizine).[5]
Mechanism of action
Levodropropizine acts by interfering with peripheral capsaicin-sensitive nerves, which form the afferent branch of the cough reflex in response to physical and chemical stimuli.[6]
References
- ^ Lee S, Nam KY, Oh J, Lee S, Cho SM, Choi YW, Hong JH (2018). "Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet". Drug Design, Development and Therapy. 12: 1413–1420. doi:10.2147/DDDT.S146958.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "Hactosec: Summary of Product Characteristics" (PDF). Retrieved 25 March 2026.
- ^ De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A (January 2012). "An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome". Cough. 8 (1): 1. doi:10.1186/1745-9974-8-1. PMC 3274450. PMID 22269875.
- ^ Chan-hyuk, Kim (September 9, 2021). "Korea United Pharm sues 15 drugmakers to protect cough suppressant's patent". Korea Biomedical Review. Retrieved July 29, 2024.
- ^ "Korea United Pharm to supply mucoactive drugs worth $52 million to Thailand". Korea Biomedical Review. September 9, 2023. Retrieved July 29, 2024.
- ^ Lavezzo A, Melillo G, Clavenna G, Omini C (June 1992). "Peripheral site of action of levodropropizine in experimentally-induced cough: role of sensory neuropeptides". Pulmonary Pharmacology. 5 (2): 143–7. doi:10.1016/0952-0600(92)90033-d. PMID 16406742.
External links